![@mem_somerville_kbin@kbin.social avatar](http://kbin.fedi.cr/media/cache/resolve/avatar_thumb/69/3f/693ff88dd7d4962d86eedddd47204be25336b8ceb196a460dcf40d8796860d7a.jpg)
![@mem_somerville_kbin@kbin.social](http://kbin.fedi.cr/media/cache/resolve/user_cover/c4/2d/c42d0b49cf39850e399fee10bc874d43d8bd0ef0ece159174bc0ec83c2cb420a.jpg)
![@mem_somerville_kbin@kbin.social avatar](http://kbin.fedi.cr/media/cache/resolve/avatar_thumb/69/3f/693ff88dd7d4962d86eedddd47204be25336b8ceb196a460dcf40d8796860d7a.jpg)
Scientist. Lacemaker.
Este perfil es de un servidor federado y podría estar incompleto. Explorar más contenido en la instancia original.
Scientist. Lacemaker.
Este perfil es de un servidor federado y podría estar incompleto. Explorar más contenido en la instancia original.
New kbin user guide (preparation for impending wave of reddit migrants in July) (kbin.social) en
This article is an x-post from m/quickstart...
Women in the History of Science | Free book download (uclpress.co.uk) en
Women in the History of Science brings together primary sources that highlight women’s involvement in scientific knowledge production around the world. Drawing on texts, images and objects, each primary source is accompanied by an explanatory text, questions to prompt discussion, and a bibliography to aid further research....
Opinion | Your Brain Has Tricked You Into Thinking Everything Is Worse (nytimes.com) en
Our biased attention means we’ll always feel like we’re living in dark times, and our biased memory means we’ll always feel like the past was brighter.
Florida’s smallest citrus crop in a century to put squeeze on shoppers (wapo.st) en
Orange juice may become pricier and less sweet over the next several months as Florida’s famous groves yield the smallest crop of citruses in nearly a century.
Editas' sickle cell CRISPR therapy shows early promise, but can it stand out against Vertex? (fiercebiotech.com) en
Editas Medicine has shared early clinical data on the cell therapy it is developing to challenge Vertex and CRISPR Therapeutics for the sickle cell market. The CRISPR-edited therapy showed clear signs of efficacy but, with its rivals awaiting FDA approval, differentiating a late-to-market challenger could be tough.